# Avidity Biosciences, Inc. — merger/definitive [completed]
Source: SEC API (secapi.ai) · situation sit_ff8bba1c41fb035562f7 · retrieved 2026-08-11T15:52:11.585Z

## Overview
Avidity Biosciences is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs), a proprietary platform combining monoclonal antibodies with RNA therapeutics to target rare genetic diseases; its pipeline includes programs in Phase 2-3 development for myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.

On October 25, 2025, Novartis AG agreed to acquire Avidity Biosciences, Inc. in an all-cash transaction valued at $72.00 per share of Company Common Stock. Prior to the merger closing, Avidity will separate its early-stage precision cardiology programs (AOC 1086 and AOC 1072) into a newly formed subsidiary, Atrium Therapeutics, Inc. (SpinCo), which will be distributed to Avidity stockholders at a ratio of one SpinCo share for every ten Avidity shares held. The merger is expected to close in the first half of 2026, subject to stockholder approval, regulatory clearances under the Hart-Scott-Rodino Act, and other customary closing conditions. Avidity's board unanimously recommends approval of the transaction.

## Terms
- Counterparty: Novartis AG · Consideration: cash · Premium: 46.0% · Price/share: $72

## Key dates
- Announced 2026-01-30 · Record 2026-01-29 · Vote 2026-02-23 · Expiry 2026-10-26 · Expected close 2026-06-30 · Completed 2026-02-27

## Timeline
- 2026-01-30 · DEFM14A (0001193125-26-031920): DEFM14A - Avidity Biosciences, Inc. — *Avidity Biosciences is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs), a proprietary platform combining monoclonal antibodies with RNA therapeutics to target rare genetic diseases; its pipeline includes programs in Phase 2-3 development for myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.* On October 25, 2025, Novartis AG agreed to acquire Avidity Biosciences, Inc. in an all-cash transaction valued at $72.00 per share of Company Common Stock. Prior to the merger closing, Avidity will separate its early-stage precision cardiology programs (AOC 1086 and AOC 1072) into a newly formed subsidiary, Atrium Therapeutics, Inc. (SpinCo), which will be distributed to Avidity stockholders at a ratio of one SpinCo share for every ten Avidity shares held. The merger is expected to close in the first half of 2026, subject to stockholder approval, regulatory clearances under the Hart-Scott-Rodino Act, and other customary closing conditions. Avidity's board unanimously recommends approval of the transaction.
  https://www.sec.gov/Archives/edgar/data/1599901/0001193125-26-031920.txt
- 2026-02-27 · 8-K (0001193125-26-079570): 8-K 8-K
  https://www.sec.gov/Archives/edgar/data/1599901/000119312526079570/d90931d8k.htm

## Citations
- 0001193125-26-031920 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526031920
- 0001193125-26-079570 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526079570